UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
April 20, 2016
Date of Report (Date of earliest event reported)
Immune Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Florida | | 000-54933 | | 59-3226705 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No. |
| 37 North Orange Ave, Suite 607, Orlando, FL | | 32801 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code888-613-8802
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425) |
| | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On April 20, 2016 Immune Therapeutics, Inc. (the “Company”) through its wholly owned subsidiary TNI BioTech International a BVI Corporation entered into a Binding Letter of Intent (“LOI”) with Super T-Cell Cancer Co., LTD (“Licensor”) a BVI Corporation. The Board of Directors of the Company unanimously approved the LOI. Pursuant to the Letter of Intent, the Company will issue 6,000,000 shares of common stock to Licensor for rights to Licensor’s technology. In addition, the Company will pay to Licensor a 12% royalty payment upon commercialization of the technology.
On April 21, 2016, the Company issued a press release in the form attached hereto as Exhibit 99.1 related to the LOI.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith.
| Exhibit No. | | Description |
| | | |
| 10.1 | | Binding Letter of Intent Between TNI BioTech International and Super T-Cell Cancer Co., LTD dated April 20, 2016. |
| | | |
| 99.1 | | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | IMMUNE THERAPEUTICS, INC. |
| | | |
| Date: April 21, 2016 | By: | /s/ Noreen Griffin |
| | | Noreen Griffin, CEO |
